Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET

Zheng, Xiangqin; Lin, Danmei; Zhang, Yulong; Lin, Yuan; Song, Jianrong; Li, Suyu

doi:10.1097/md.0000000000008842

Cited by 48 publications

(33 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Much research has focused on the role of myo-inositol as an insulin-sensitizing agent in polycystic ovary syndrome 88 and in improving oocyte quality and outcomes of assisted reproduction. 89 …”

Section: Myo-inositolmentioning

confidence: 99%

Safety and efficacy of supplements in pregnancy

Brown¹,

Wright²

2020

Nutrition Reviews

View full text Add to dashboard Cite

Pregnancy is a time where expectant mothers often focus on their diet to improve their own health and to preserve the future health of their children. There is much conflicting information in the public domain about the safety and/or efficacy of nutritional supplements during pregnancy. Despite this, the market for supplements is growing. This review discusses the roles of critical nutrients in pregnancy and the available evidence on the use of supplements to reduce risks and improve maternal and fetal outcomes. Recommendations are made for pregnant women, taking into account safety data and tolerable upper intakes set for pregnant women. It is important for dieticians, nutritionists, physicians, and other healthcare providers to be able to offer accurate and evidence-based advice on supplement use in pregnancy. Routine supplementation may not be necessary for all, but individuals at risk are identified.

show abstract

Section: Myo-inositolmentioning

confidence: 99%

Safety and efficacy of supplements in pregnancy

Brown¹,

Wright²

2020

Nutrition Reviews

View full text Add to dashboard Cite

show abstract

“…Inositol has two major stereoisomers: myo-inositol (MYO) and Dchiro-inositol (DCI). MYO supplements have been observed to improve the metabolic profile and hyperandrogenism of women with PCOS [4,5], in addition to increasing the clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET, probably improving the quality of embryos and reducing the number of unsuitable oocytes [6]. However, a recent systematic review showed that MYO supplementation is not sufficient to improve oocyte maturation, embryo quality or the pregnancy rate [7].…”

Section: Introductionmentioning

confidence: 99%

Comparison of the effect of two combinations of myo-inositol and D -chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial

Mendoza

Díaz-Ropero

Aragón

et al. 2019

Gynecological Endocrinology

View full text Add to dashboard Cite

The purpose of this study was to evaluate the effect of two doses of D-chiro-inositol (DCI) in combination with Myo-inositol (MYO) in women with PCOS undergoing ICSI. This was a multicenter controlled, randomized, double-blind parallel group study with two MYO-DCI formulations for 12 weeks. The study group (SG) was administered 550 mg of MYO þ 150 mg of DCI twice daily; the control group (CG) was administered 550 mg of MYO þ 13.8 mg of DCI twice daily. The participants comprised 60 women with PCOS undergoing ICSI. At baseline, no differences were found between the two groups regarding age, BMI, HOMA-IR or testosterone levels. The pregnancy and live birth rates were significantly higher in the SG than in the CG (65.5 vs. 25.9 and 55.2 vs. 14.8, respectively) [risk ratio (RR) ¼ 0.4; 95%CI (0.2, 0.79); p ¼ .003 and RR ¼ 0.27; 95%CI (0.10, 0.70); p ¼ .002 respectively]. The risk of ovarian hyperstimulation syndrome (OHSS) was lower in the SG (3.44 vs. 18.5%, p ¼ .07). The combination of MYO-DCI at high doses of DCI improves the pregnancy rates and reduces the risk of OHSS in women with PCOS undergoing ICSI.

show abstract

“…Interestingly, another review by Zheng et al stated that MI has a role in improving the number of good-quality embryos and reducing the number of germinal vesicles and degenerated oocytes. However, both PCOS and non-PCOS trials were included in their study [48].…”

Section: No Journal Authormentioning

confidence: 99%

Myo-Inositol’s Role in Assisted Reproductive Technology: Evidence for Improving the Quality of Oocytes and Embryos in Patients With Polycystic Ovary Syndrome

Gupta¹,

Khan²,

Islam³

et al. 2020

Cureus

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is one of the most common causes of subfertility, and it is characterized by hormonal dysregulation like insulin resistance. Various measures have been taken in the past to overcome this insulin resistance to improve fertility treatment outcomes. The current paper aims to review and compare the existing studies and literature to assess the impact of myo-inositol (MI) on oocyte and embryo quality in assisted reproductive technology (ARTs). We thoroughly searched the PubMed and Google Scholar databases by using the keywords "PCOS, polycystic ovarian syndrome, inositol, oocyte quality, embryo quality, assisted conception, ART, IVF, and in vitro fertilization." Nine articles were finalized for review in this paper. Many of the reviewed studies have shown a trend toward the improvement of embryo quality in women with PCOS after MI supplementation; however, there is a lack of statistically significant evidence to support the use of MI in enhancing the quality of oocyte and/or embryo. Clear evidence regarding the role of MI in enhancing the quality of oocyte and embryo in PCOS is limited. A well-controlled, large, randomized controlled trial is required to definitively accept or refute its role.

show abstract

Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET

Cited by 48 publications

References 35 publications

Safety and efficacy of supplements in pregnancy

Safety and efficacy of supplements in pregnancy

Comparison of the effect of two combinations of myo-inositol and D -chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial

Myo-Inositol’s Role in Assisted Reproductive Technology: Evidence for Improving the Quality of Oocytes and Embryos in Patients With Polycystic Ovary Syndrome

Contact Info

Product

Resources

About